Alterations in the expression of human kallikrein-related peptidases (KLKs) have been described in patients with Alzheimer’s disease (AD). We elucidated the suitability of KLK6, KLK8 and KLK10 to distinguish AD from NC and explored associations with established AD biomarkers. KLK levels in cerebrospinal fluid (CSF), as determined by ELISA, were compared between 32 AD patients stratified to A/T/(N) system with evidence for amyloid pathology and of 23 normal controls with normal AD biomarkers. Associations between KLK levels and clinical severity, CSF and positron emission tomography (PET) based AD biomarkers were tested for. Levels of KLK6 and KLK10 were significantly increased in AD. KLK6 differed significantly between AD A+/T+/N+ and AD A+/T−/N+ or NC with an AUC of 0.922. CSF pTau and tTau levels were significantly associated with KLK6 in AD. KLK6 deserves further investigations as a potential biomarker of Tau pathology in AD.

中文翻译：

---

激肽释放酶相关肽酶 6 和 10 在阿尔茨海默病患者的脑脊液中升高，并与 CSF-TAU 和 FDG-PET 相关

阿尔茨海默病 (AD) 患者中已经描述了人类激肽释放酶相关肽酶 (KLK) 表达的改变。我们阐明了 KLK6、KLK8 和 KLK10 区分 AD 和 NC 的适用性，并探索了与已建立的 AD 生物标志物的关联。通过 ELISA 测定的脑脊液 (CSF) 中的 KLK 水平在 32 名具有淀粉样蛋白病理学证据的 A/T/(N) 系统分层的 AD 患者和 23 名具有正常 AD 生物标志物的正常对照之间进行了比较。测试了 KLK 水平与临床严重程度、CSF 和基于正电子发射断层扫描 (PET) 的 AD 生物标志物之间的关联。AD 中 KLK6 和 KLK10 的水平显着增加。KLK6 在 AD A+/T+/N+ 和 AD A+/T-/N+ 或 NC 之间有显着差异，AUC 为 0.922。脑脊液 pTau 和 tTau 水平与 AD 中的 KLK6 显着相关。